TRIUMF

Canada's particle accelerator centre

How nuclear physics can treat cancer

Radiotherapy at TRIUMF

Cornelia Hoehr
Scientist
Deputy Associate Laboratory Director | Life Sciences

Introduction

Tourism Vancouver

Introduction

- TRIUMF – Tri University Meson Facility,
- since 1968, now 20 member universities
- Canada's particle accelerator centre



Member Universities:

- University of Alberta
- University of British Columbia
- University of Calgary
- Carlton University
- University of Guelph
- University of Manitoba
- Université de Montréal
- Queen's University
- University of Regina
- Simon Fraser University
- University of Toronto
- University of Victoria
- York University

Associate Members:

- McGill University
- McMaster University
- University of Northern BC
- Saint Mary's University
- Université de Sherbrooke
- Western University
- University of Winnipeg

TRIUMF - nuclear physics lab.

Expertise in:

- Accelerator technology
- Accelerator operation
- Detectors
- Targets for isotope production
- Interaction of particles







Medical Application @ TRIUMF

Applicable to medicine



Cancer


Cancer occurence
colorectal cancer, 10%
bladder cancer, 7%
non-Hodgkin lymphoma, 5%
lung cancer, 15%
skin melanoma, 5%
kidney cancer, 4%
oral and pharyngeal cancer, 3%
prostate cancer, 25%
leukemia, 3%
pancreatic cancer, 3%
other, 20%


Cancer mortality
prostate cancer, 10%
colorectal cancer, 8%
pancreatic cancer, 6%
liver & intrahepatic bile duct, 4%
lung cancer, 31%
leukemia, 4%
esophageal cancer, 4%
bladder cancer, 3%
non-Hodgkin lymphoma, 3%
other, 24%
kidney cancer, 3%


Cancer occurence
colorectal cancer, 10%
endometrial cancer, 7%
lung cancer, 14%
non-Hodgkin lymphoma, 4%
thyroid cancer, 4%
breast cancer, 26%
Skin melanoma, 4%
ovarian cancer, 3%
kidney cancer, 3%
other, 22%
leukemia, 3%


Cancer mortality
colorectal cancer, 9%
pancreatic cancer, 6%
breast cancer, 15%
ovarian cancer, 6%
non-Hodgkin lymphoma, 3%
leukemia, 3%
uterine cancer, 3%
liver & intrahepatic bile duct, 2%
lung cancer, 26%
brain and other nervous system, 2%
other, 25%

- Surgery
- Chemotherapy
- Ionizing radiation





DNA break



- DNA (Deoxyribonucleic acid): genetic instructions for development and functioning
- Cell needs information from DNA for survival

- Single helix break easy to repair
- Double helix break more difficult to repair
- Cell can not survive

- **Radiotherapy: as many double helix breaks in cancer cells as possible with as few double breaks as possible in healthy cells**



Ionizing Radiation



LET – Linear Energy Transfer



Linear Energy Transfer (LET): Energy transferred (ionization, secondary electrons) per unit distance

LET – Linear Energy Transfer



Low LET – photons, electrons, protons, indirect damage via free radical formation

High LET – ions, neutrons, protons, direct damage

RBE - Relative Biological Effectiveness

X rays: 1
Protons: 2
Heavier ions: 20



LET – Linear Energy Transfer



Low LET – photons, electrons, protons, indirect damage via free radical formation

High LET – ions, neutrons, protons, direct damage

OER – Oxygen Enhancement Ratio

- High LET radiation – low OER
- OER for x rays = up to 4
- OER for ions = 1



LET – Linear Energy Transfer



Low LET – photons, electrons, protons, indirect damage via free radical formation

High LET – ions, neutrons, protons, direct damage



External beam therapy

- **Electrons** only used for surface tumours
- **X-rays** (6-18 MV) most commonly used radiotherapy, many techniques to spare healthy tissue (3D conformal beams, image guided delivery, real-time motion tracking etc.), compact and cost efficient
- **Protons** need 230 MeV accelerator for clinical use, large facility, expensive



FLASH effect

Conventional dose rate ~ 0.03 Gy/s

- In 20 – 30 fractions to affect all cell cycle phases, and to reach the hypoxic centre of a tumour



Vozenin *et al.*, 2018

FLASH effect

Conventional dose rate ~ 0.03 Gy/s

- In 20 – 30 fractions to affect all cell cycle phases, and to reach the hypoxic centre of a tumour

FLASH dose rate < 40 Gy/s

- Lower toxicity in healthy tissue but same tumour control
- Effect only consistently observed *in-vivo*, not *in-vitro*
- Oxygen – depletion hypothesis, healthy tissue becomes basically hypoxic
- To reach high dose rates – remove target….. **electron beam**



Vozenin *et al.*, 2018

FLASH effect

Conventional dose rate ~ 0.03 Gy/s

- In 20 – 30 fractions to affect all cell cycle phases, and to reach the hypoxic centre of a tumour

FLASH dose rate < 40 Gy/s

- Lower toxicity in healthy tissue but same tumour control
- Effect only consistently observed *in-vivo*, not *in-vitro*
- Oxygen – depletion hypothesis, healthy tissue becomes basically hypoxic
- To reach high dose rates – remove target….. **electron beam**

Bourhis *et al.*, 2019

Electron FLASH







- FLASH in Vancouver
- Around 260 Gy/s
- Data still being analyzed

Andrew Minchinton, BC Cancer

Photon FLASH



- Electron gun 300 keV 10 mA (CW)
- Three accelerating superconductive cryomodules
- Irradiation stations:
  - Low energy (CTS – 300 keV)
  - High energy (EABD – up to 30 MeV)
  - Medium energy (EMBD - up to 10 MeV)



Magdalena Bazalova-Carter, UVic
Alexander Gottberg, TRIUMF

Photon FLASH



- Electron gun 300 keV 10 mA (CW)
- Three accelerating superconductive cryomodules
- Two side irradiation stations:
  - Low energy (CTS – 300 keV)
  - High energy (EABD – up to 30 MeV)
  - Medium energy (EMBD - up to 10 MeV)





Magdalena Bazalova-Carter, UVic
Alexander Gottberg, TRIUMF

FLASH – DoseEq @ 10 MeV



Average dose rate up to ~ 300 Gy/s



Magdalena Bazalova-Carter, UVic
Alexander Gottberg, TRIUMF

What's next?

- Manufacture, installation and testing until summer 2020
- Experiments with biological samples fall 2020



Magdalena Bazalova-Carter, UVic
Alexander Gottberg, TRIUMF

Hans Bethe

$$-\frac{dT}{dx} = \frac{4\pi e^4 z^2}{m v^2} Z \ln \frac{2 m v^2}{E},$$

Zur Theorie des Durchgangs schneller Korpuskularstrahlen durch Materie, Annalen der Physik. vol. 397, pp. 325-400, 1930



Radiological Use of Fast Protons, Radiology vol. 47, pp. 487-91, 1946

Robert Wilson


Proton and heavy ion therapy centers
30
31
4
2
20
Currently 91 centers in operation, 46 under construction, 21 in planning

Proton Therapy @ TRIUMF

- Clinical operation since 1995
- Canada's only proton therapy facility
- Ocular melanomas
- Clinical treatments ended Feb 2019



Beamline 2C1





PT Treatment Results

Summary paper with 59 patients
(E. Tran et al., Int. J. Radiat. Oncol. Biol. Phys. 83 (2012) 1425)

- 20 patients T1, 28 patients T2, 11 patients T3
- Median tumor size: diameter 11.4 mm, 3.5 mm thick
- Median follow-up time 63 month
- 19 patients treated with 54 CGE and 40 patients treated with 60 CGE
- **5-year local control rate 91%**
(T1 100%, T2 93%, T3 59%) **and 97%** with 60 CGE, 83% 54 CGE
- **Metastasis-free survival rate 82%** (T1 94%, T2 84%, T3 47%)
- 5-year neovascular glaucoma 31% (T1-2 23%, T3 68%)
- Enucleation T1 0%, T2 14%, T3 72%



before PT

after PT

PT Small Field Treatment





- Typical sensors for dosimetry larger than treatment volume
- Optical fibers can have excellent spatial resolution
- Dose and dose rate independent

Cheryl Duzenli, BC Cancer
Sylvain Girard, St. Etienne

Novel Scintillators for PT Dosimetry





Cheryl Duzenli, BC Cancer
Sylvain Girard, St. Etienne

Novel Scintillators for PT Dosimetry



$$\frac{dL}{dx} = \frac{S\frac{dE}{dx}}{1 + k_B\frac{dE}{dx} + C\left(\frac{dE}{dx}\right)^2}$$

- Empirical Craun-Birks equation
- Correction of quenching
- Not practical for Proton Therapy!

Cheryl Duzenli, BC Cancer
Sylvain Girard, St. Etienne

Novel Scintillators for PT Dosimetry





Cheryl Duzenli, BC Cancer
Sylvain Girard, St. Etienne

PT Range verification



PT Range verification



PT Range verification



PT Range verification



PT Range verification



PT Range verification







PT Range verification



PT Range verification



PT Range verification



- Summer 2019: experiment with HPGe detector
- Data currently being analyzed by Eva and Christina



Proton FLASH?



- PT facility (2C1) at TRIUMF limited to 6 nA, or ~ 0.2 Gy/s
- Main cyclotron able to extract 100 uA into 2C4, or up to 3,333 Gy/s

- Will there be a FLASH effect with protons?
- How do you ensure range verification?

Andrew Minchinton, BC Cancer
Oliver Kester, TRIUMF

External beam therapy with ions



HIT website

Targeted α Therapy (TAT)

Kratochwil *et al., J. Nuc. Med.* 2016;57(12):1941–1944.

Targeted α Therapy (TAT)



- 11 clinical trials (^{225}Ac and ^{213}Bi)
- > 640 patients (60-80% showed response)
- Want up to 50,000 patient doses a year (120 Ci)

Kratochwil *et al., J. Nuc. Med.* 2016;57(12):1941–1944.

Current ^{225}Ac Production

Primary ^{225}Ac sources:

- ^{229}Th/^{225}Ac generator ($t_{1/2}$ ~ 7880 y) sourced via legacy stockpile, ORNL, ITU
- Alternatives sought
- ^{226}Ra irradiation
- Tri-Lab efforts ^{232}Th(p,x) spallation

Global production is ~10 Ci per year

- Promising early clinical trial results
- Supply vs demand is out of balance, but market needs to be nurtured, and supply needs to increase and be reliable



J.W. Weidner et al. Appl. Radiat. Isotop. 2012, 70, 2602

- ^{225}Ac production via Th spallation demonstrated at small scales:

LANL	50 - 200, 800 MeV
INR RAS	40 - 90 MeV

α emitters


ISAC - II
HIGH ENERGY EXPERIMENTAL HALL
EMMA
SUPERCONDUCTING LINAC
SCA
SCB
SCC
DSCR
MSCA
DTL
HEBT
ISAC - I
TITAN
DRAGON
TUDA
LEBT
DNMR
RACON EDM
TR 30-2 ISOTOPE PRODUCTION CYCLOTRON
TR 30-1 ISOTOPE PRODUCTION CYCLOTRON
CP 42 ISOTOPE PRODUCTION CYCLOTRON
TR 13 ISOTOPE PRODUCTION CYCLOTRON
MAIN OFFICE BUILDING
ATLAS TIER-1 CENTRE BUILDING
TARGET HALL 2
TARGET HALL 1
REMOTE HANDLING FACILITY
SERVICE BRIDGE
MDS NORDION COMPLEX
HEALTH SCIENCE BUILDING
BL4N(p)
PROTON HALL EXTENSION
e-LINAC
PROTON HALL
CYCLOTRON VAULT
BL2A(p)
PROTON THERAPY FACILITY
MESON HALL
UCN FACILITY
M9B
M9A
M20C
M20D
MESON HALL EXTENSION CLEAN ASSEMBLY AND HOT CELLS
500 MeV ISOTOPE PRODUCTION FACILITY
BL1A(p)
1AT1
1AT2
BL2C(p) SOLID TARGET FACILITY
M15 (μ)
H⁻ ION SOURCE
H⁻ POLARIZED ION SOURCE
e-LINAC COOLING PLANT

Isotope Accelerator Program: Isotope Production Facility

Isotope production using TRIUMF's
500 MeV infrastructure

IPF (BL1A)
Intermediate activity (MBq), spallation

- Routine, independent production



500 MeV Isotope Production Facility

Spallation Reaction on ^{232}Th with 500 MeV Protons

- Hundreds of co-produced isotopes including
- **^{225}Ra, ^{225}Ac**, ^{224}Ra, ^{223}Ra, ^{213}Bi, ^{212}Pb, ^{212}Bi, **$^{209/211}$At**





^{232}Th spallation produces both Ac and Ra isotopes



^{225}Ac + ^{224}Ac + ^{226}Ac + ^{227}Ac

$t_{1/2}$ = 9.9 d | $t_{1/2}$ = 3 h | $t_{1/2}$ = 29 h | $t_{1/2}$ = 22 y

concerns (from some) about ^{227}Ac content and impact on waste management — no consensus

directly-produced ^{225}Ac

^{232}Th spallation produces both Ac and Ra isotopes



^{227}Ra + $t_{1/2}$ = 42 min

^{225}Ra + $t_{1/2}$ = 14.9 d

^{228}Ra + $t_{1/2}$ = 5.8 y

^{224}Ra + $t_{1/2}$ = 3.6 d

^{226}Ra $t_{1/2}$ = 1600 y

^{225}Ac + $t_{1/2}$ = 9.9 d

^{224}Ac + $t_{1/2}$ = 3 h

^{226}Ac + $t_{1/2}$ = 29 h

^{227}Ac $t_{1/2}$ = 22 y

concerns (from some) about ^{227}Ac content and impact on waste management — no consensus

directly-produced ^{225}Ac

^{232}Th spallation produces both Ac and Ra isotopes



^{227}Ra + ($t_{1/2}$ = 42 min)

^{225}Ra + ($t_{1/2}$ = 14.9 d)

^{228}Ra + ($t_{1/2}$ = 5.8 y)

^{224}Ra + ($t_{1/2}$ = 3.6 d) → ^{224}Rn

^{226}Ra ($t_{1/2}$ = 1600 y) → ^{222}Rn

rapid decay

^{225}Ac + ($t_{1/2}$ = 9.9 d)

^{224}Ac + ($t_{1/2}$ = 3 h)

^{226}Ac + ($t_{1/2}$ = 29 h)

^{227}Ac ($t_{1/2}$ = 22 y)

concerns (from some) about ^{227}Ac content and impact on waste management

directly-produced ^{225}Ac

^{232}Th spallation produces both Ac and Ra isotopes



^{227}Ra + $t_{1/2}$ = 42 min

^{225}Ra + $t_{1/2}$ = 14.9 d

^{228}Ra + $t_{1/2}$ = 5.8 y

^{224}Ra + $t_{1/2}$ = 3.6 d → ^{224}Rn

^{226}Ra $t_{1/2}$ = 1600 y → ^{222}Rn

rapid decay

^{225}Ac + $t_{1/2}$ = 9.9 d

^{224}Ac + $t_{1/2}$ = 3 h

^{226}Ac + $t_{1/2}$ = 29 h

^{227}Ac $t_{1/2}$ = 22 y

concerns (from some) about ^{227}Ac content and impact on waste management

directly-produced ^{225}Ac

^{225}Ac + $t_{1/2}$ = 9.9 d

^{228}Ac + $t_{1/2}$ = 6 h

generator-produced ^{225}Ac

FLUKA: Primary vs Secondary ^{225}Ac

Process steps:
1) Th Irradiation
2) Ra/Ac separation 1 week EOB – gives primary Ac fraction
3) Recovered Ra allowed to sit for 17.5 days
4) Ra/Ac separation – gives secondary Ac fraction

Primary Ac Fraction			
days from Ra/Ac isolation	0	1	5
Ac-225 [MBq]	**42.2**	**39.4**	**29.9**
Ac-228/Ac-225 [%]	0.039	0.003	0.000
Ac-227/Ac-225 [%]	0.185	0.198	0.261
Ac-226/Ac-225 [%]	16.020	9.740	1.330

Secondary Ac Fraction		
days from Ra/Ac isolation	0	2
Ac-225 [MBq]	**2.2**	**1.9**
Ac-228/Ac-225 [%]	0.882	0.003
Ac-227/Ac-225 [%]	9.951E-09	9.949E-09
Ac-226/Ac-225 [%]	0.000	0.000

Target Station



- Up to 6 cassettes, 12 targets
- Targets immersed in circulating water bath
- Thermocouples monitor target, water temperatures
- Cassettes can be moved without beam on/off

Design and ANSYS simulations









Thorium irradiations

Irradiation parameters

- integrated current 2640 µA*h, over **36-40 h**
- 66-73 µA, 454 MeV

Results (n = 3)

- (521 ± 18) MBq ^{225}Ac and (95 ± 24) MBq ^{225}Ra at EOB
- saturation yields 72 MBq/µA (^{225}Ac), 19 MBq/µA (^{225}Ra)
- (319 ± 11) MBq ^{225}Ac and (69 ± 17) MBq ^{225}Ra at transfer to radiochemistry

What's next?

- **x12 increase** in yield by irradiating 12 targets
- **x10 increase** in yield by irradiating for full ^{225}Ra half life (15 days)
- Further increase from thicker target and higher current require re-evaluation of target and safety

Targeted α Therapy (TAT)



ARIEL Medical Target Station



Isotope production using
TRIUMF's
500 MeV infrastructure

ARIEL/H^+
High activity (GBq), spallation

- Enable radiopharmaceutical development and clinical trials

Francois Benard, BC Cancer
Alexander Gottberg, TRIUMF

ARIEL Medical Target Station

- 400 mCi (15 GBq) ^{225}Ac per target (FLUKA)
- Irradiation schedule decoupled from science target
- ARIEL Proton Station commissioning scheduled for 2024/5 – 10 M CFI grant





Francois Benard, BC Cancer
Alexander Gottberg, TRIUMF

Summary


ISAC - II
HIGH ENERGY EXPERIMENTAL HALL
EMMA
SUPERCONDUCTING LINAC
SCA
SCB
SCC
DSCB
TIGRESS
HERACLES
TR 30-2 ISOTOPE PRODUCTION CYCLOTRON
DTL
HEBT
ISAC - I
TITAN
DRAGON
TUDA
LEBT
ATLAS TIER-1 CENTRE BUILDING
TARGET HALL 2
TARGET HALL 1
REMOTE HANDLING FACILITY
SERVICE BRIDGE
MDS NORDION COMPLEX
TR 35-1 ISOTOPE PRODUCTION CYCLOTRON
CP 42 ISOTOPE PRODUCTION CYCLOTRON
TR 13 ISOTOPE PRODUCTION CYCLOTRON
TAT
Photon FLASH
PT
PROTON HALL EXTENSION
PROTON HALL
CYCLOTRON VAULT
PROTON THERAPY FACILITY
UCN FACILITY
MESON HALL
MESON HALL EXTENSION CLEAN ASSEMBLY AND HOT CELLS
500 MeV ISOTOPE PRODUCTION FACILITY
SOLID TARGET FACILITY
H⁻ ION SOURCE
H⁻ POLARIZED ION SOURCE

Acknowledgment

TRIUMF Life Sciences Division

TRIUMF accelerator division, operations and machine shops

Collaborators

- Cheryl Duzenli (BC Cancer)
- Francois Bénard (BC Cancer)
- Andrew Minchinton (BC Cancer)
- Andrew Jirasek (UBC)
- Boris Stoeber (UBC)
- Dennis Muecher (Guelph)
- Magdalena Bazalova-Carter (UVic)
- Sylvain Girard (St Etienne, France)
- Sinead O'Keeffe (Limerick, Ireland)

New Frontiers in Research Fund
Fonds Nouvelles frontières en recherche

Natural Resources Canada Ressources naturelles Canada
Canada

NSERC CRSNG

INNOVATION.CA
CANADA FOUNDATION FOR INNOVATION | FONDATION CANADIENNE POUR L'INNOVATION

CIHR IRSC
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada

Canadian Cancer Society

TRIUMF

Canada's particle accelerator centre

Centre canadien d'accélération des particules

Thank you!
Merci!

Follow us at TRIUMFLab

TRIUMF: Alberta | British Columbia | Calgary | Carleton | Guelph | McGill | Manitoba | McMaster | Montréal | Northern British Columbia | Queen's | Regina | Saint Mary's | Simon Fraser | Toronto | Victoria | Western | Winnipeg | York

External: Pion- beam Treatment



- Pion - subatomic particle, meson
- In nuclei, glue to hold protons and neutrons
- Some are charged
- Have Bragg peak, little damage to surrounding tissue, high LET in Bragg peak
- Lots of damage at Bragg peak ('pion star')







Pion-beam Treatment at TRIUMF



- Study from 1980 – 1994 (over 300 patients), one of only three in the world
- Brain tumors (glioblastoma) and prostate cancer

- Result of study: no advantage over conventional photon therapy



Fig. 2. Overall survival for both treatment groups. Median survivals are: photons, 10 months; pions, 10 months. Log rank: $p = 0.22$.

Int. J. Radiation Oncology Biol. Phys. **37** 491 (1997)